On 2025‑10‑21 Galapagos NV announced its intention to wind down its cell therapy business after a comprehensive strategic review. The decision followed a limited number of non‑binding offers that did not meet the company’s terms, and the board approved the intention unanimously, excluding two Gilead‑appointed directors who recused themselves.
The wind‑down will affect approximately 365 employees across Europe, the U.S., and China, and will close sites in Leiden, Basel, Princeton, Pittsburgh, and Shanghai. Galapagos estimates operating costs of €100‑125 million from Q4 2025 through 2026 and one‑time restructuring costs of €150‑200 million in 2026. The decision aims to reallocate capital to new transformational business development opportunities.
Galapagos will continue to manage its non‑cell‑therapy activities from its headquarters in Mechelen, Belgium, while pursuing strategic transactions to build a pipeline of novel therapeutics. Legal advisors include Paul Weiss, Linklaters, and Rutgers & Posch, and Morgan Stanley & Co. International plc is the financial advisor. The company will provide an updated 2025 cash outlook with its third‑quarter earnings in early November.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.